About the American Society of Breast Surgeons (ASBS)
In the organization’s own words, “The American Society of Breast Surgeons, the primary leadership organization for general surgeons who treat patients with breast disease, is committed to continually improving the practice of breast surgery by serving as an advocate for surgeons who seek excellence in the care of breast patients. This mission is accomplished by providing a forum for the exchange of ideas and by promoting education, research, and the development of advanced surgical techniques. Founded in 1995, the Society has grown to more than 3000 members in the United States and 35 countries throughout the world.”
The Society’s Annual Meeting, April 26-30, 2017 in Las Vegas, is the community’s greatest opportunity to connect, collaborate and collectively advance the standard of care for tens of thousands of breast cancer patients.
Negative margins in TARGiT IORT: Methods and techniques for achieving the most favorable result
Dr. Dennis Holmes, M.D., Stephanie Valente, D.O., Calvin Ridgeway, M.D.
The Dilon Devices and Carl Zeiss Meditec teams welcome ASBrS 2017 attendees to join us for breakfast on Saturday, April 29th chaired by Dr. Dennis Holmes, M.D., F.A.C.S., Dr. Stephanie Valente, D.O., and Dr. Calvin Ridgeway, M.D.
Dr. Dennis Holmes, M.D.
Dr. Holmes is an internationally renowned breast cancer surgeon, researcher and innovator. Sought out by patients across Southern California and across the U.S., he specializes in minimally-invasive breast surgery, including oncoplastic surgery, hidden-scar nipple-sparing mastectomy, intraoperative radiotherapy, cryoablation (cancer tumor freezing), and lymph node-sparing surgery. He currently serves as Interim Director of the Margie Petersen Breast Center at St. John’s Health Center, and formerly held the positions of Chief Breast Surgeon and Medical Director of the Los Angeles Center for Women’s Health, and Chief Breast Cancer Surgeon, and Breast Cancer Research Committee Co-Chair at the University of Southern California (U.S.C.) Kenneth Norris Comprehensive Cancer Center.
Dr. Stephanie Valente, D.O.
Dr. Valente is a fellowship-trained breast surgeon for Cleveland Clinic who specializes in the treatment of breast cancer as well as benign breast disease. She is certified by the American Board of Surgery in General Surgery with fellowship training in Breast Surgical Oncology. Dr. Valente earned her medical degree from Ohio University College of Osteopathic Medicine. She completed her surgical residency at Akron City Hospital and her breast fellowship at the University of Southern California.
Dr. Calvin Ridgeway, M.D.
Dr. Ridgeway is a board-certified surgical oncologist that specializes in breast cancer and skin cancer. He has been in practice for 20 years. He began his career as a general surgeon for the United States Air force at Kirtland Air Force Base in Albuquerque. In 2008, Dr. Ridgeway joined Lovelace Women’s Hospital to start the first accredited Breast Care Center in New Mexico. He was a founding member of the New Mexico Cancer Care Alliance and currently serves as the co-chair of its board of directors. He is an active member of the Society of Surgical Oncology, the American College of Surgeons and the American society of Breast Surgeons.
Since beginning his career in Albuquerque, Dr. Ridgeway has opened multiple clinical trials for the treatment of breast cancer and melanoma. He currently serves as a volunteer faculty member at the University of New Mexico and at St. Francis University in Albuquerque.
Drs. Holmes, Valente and Ridgway will lead a discussion over breakfast on techniques for achieving negative margins when employing TARGiT Intraoperative Radiation Therapy for breast conserving surgery patients. The program will combine presentation and panel discussion on two synergistic technologies: MarginProbe to overcome the challenges with margins in BCS; and TARGiT Intrabeam on proper patient selection, management, and follow-up of IORT patients.
Who we want to meet
Amidst the rapid advancements in surgical techniques and technologies for breast cancer treatment, we want to meet anyone involved in treating breast cancer patients in the interest of discussing MarginProbe’s capabilities and the latest available clinical data.
We want ASBrS 2017 attendees to know that MarginProbe enables them to more consistently eliminate cancerous tissue without the need for second surgeries. As a result, patients are returned to health quicker and without the anguish of a second surgery or prolonged treatment. By offering this superior treatment experience, healthcare providers can better meet patient needs – and, therefore, can market their services as superior alternatives to more traditional approaches.Leading breast surgeons including Drs. Joseph Contino, Melanie Friedlander, Vincent Reid and many more believe in the MarginProbe advantage for their practices and their patients.
The Wall Street Journal: “If Surgery Got Cancer in One Try.”
“In a randomized trial involving 596 patients in 21 institutions in America and Israel, Dr. Schnabel found that the MarginProbe reduced the numbers of patients requiring second surgeries by 26%.”
You can find the MarginProbe team at the aforementioned breakfast on Saturday morning and throughout ASBS 2017 at booth #413.
To schedule a meeting in advance, contact Whitney Hausmann at email@example.com.